COVID-19 vaccines

Dallas-Based Vaxxinity Prepares for $100M IPO; Aims to Turn Immune Systems Into ‘Antibody Factories’

by | Nov 8, 2021
Vaxxinity's COVID-19 vaccine candidate is "super safe and mild and doesn’t bring recipients down for a couple of days with flu-like symptoms," says the company's co-founder and CEO, Mei Mei Hu. Unlike mRNA vaccines from Modern and Pfizer, Vaxxinity says its protein peptide-based platform is based on tech that led to a vaccine for foot-and-mouth disease in livestock.